Obesity Surgery

, Volume 19, Issue 9, pp 1250–1255 | Cite as

Serum Magnesium Status After Gastric Bypass Surgery in Obesity

  • Hans-Erik JohanssonEmail author
  • Björn Zethelius
  • Margareta Öhrvall
  • Magnus Sundbom
  • Arvo Haenni
Research Article



Roux-en-Y gastric bypass (RYGBP) has become a common surgical procedure to treat morbid obesity. Furthermore, it strongly reduces the incidence of type 2 diabetes and mortality. However, there is scant information on how magnesium status is affected by RYGBP surgery. Previous bariatric surgery methods, like jejunoileal bypass, are associated with hypomagnesemia.


Twenty-one non-diabetic morbidly obese patients who underwent RYGBP were evaluated before and 1 year after surgery and compared to a matched morbidly obese control group regarding serum magnesium. Groups were matched regarding weight, BMI, abdominal sagittal diameter and fasting glucose, blood pressure, and serum magnesium concentrations before surgery in the RYGBP group.


The serum magnesium concentrations increased by 6% from 0.80 to 0.85 mmol/l (p = 0.019) in the RYGBP group while a decrease by 4% (p = 0.132) was observed in the control group. The increase in magnesium concentration at the 1-year follow-up in the RYGBP group was accompanied by a decreased abdominal sagittal diameter (r2 = 0.32, p = 0.009), a lowered BMI (r2 = 0.28, p = 0.0214), a lowered glucose concentration (r2 = 0.28, p = 0.027) but not by a lowered insulin concentration (p = 0.242), a lowered systolic (p = 0.789) or a lowered diastolic (p = 0.785) blood pressure.


RYGBP surgery in morbidly obese subjects is characterized by reduced visceral adiposity, lowered plasma glucose, and increased circulating magnesium concentrations. The inverse association between lowered central obesity, lowered plasma glucose and increased magnesium concentrations, needs further detailed studies to identify underlying mechanisms.


Morbid obesity Gastric bypass surgery Magnesium 



Funding was by research grants from The Family Ernfors Fund for Diabetes Research, the Swedish Diabetes Association, the Erik, Karin and Gösta Selander fund, Uppsala University, and The Thuring family foundation.


  1. 1.
    World Health Organization. Obesity and overweight: fact sheet no 3011. Geneva; 2006.Google Scholar
  2. 2.
    Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefGoogle Scholar
  3. 3.
    Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.CrossRefGoogle Scholar
  4. 4.
    Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.CrossRefGoogle Scholar
  5. 5.
    Sharma A, Dabla S, Aqrawal RP, et al. Serum magnesium: an early predictor of course and complications of diabetes mellitus. J Indian Med Assoc. 2007;105(1):16, 18, 20.PubMedGoogle Scholar
  6. 6.
    Guerrero-Romero F, Rodriguez-Moran M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol. 2002;39:209–13.CrossRefGoogle Scholar
  7. 7.
    Haglin L, Tornkvist B, Backman L. Prediction of all-cause mortality in a patient population with hypertension and type 2 DM by using traditional risk factors and serum-phosphate, -calcium and -magnesium. Acta Diabetol. 2007;44(3):138–43.CrossRefGoogle Scholar
  8. 8.
    Jorgensen S, Olesen M, Gudman-Hoyer E. A review of 20 years of jejunoileal bypass. Scand J Gastroenterol. 1997;32(4):334–9.CrossRefGoogle Scholar
  9. 9.
    Bloomberg RD, Fleisman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Review article. Obes Surg. 2005;15:145–54.CrossRefGoogle Scholar
  10. 10.
    Correa FH, Nogueira VG, Bevilacqua, et al. Insulin resistance and secretion assessment across a range of glucose tolerance from normal individuals through diabetes. Arg Bras Endocrinol Metabol. 2007;51(9):1498–505.CrossRefGoogle Scholar
  11. 11.
    Sundbom M, Gustavsson S. Bariatric surgery. Clin Dermatol. 2004;22:325–31.CrossRefGoogle Scholar
  12. 12.
    Van Gaal L, Delvigne C, Vandewoude M, et al. Evaluation of magnesium before and after jejuno-ileal versus gastric bypass surgery for morbid obesity. J Am Coll Nutr. 1987;5:397–400.CrossRefGoogle Scholar
  13. 13.
    Diniz Mde F, Diniz MT, Sanches SR, et al. Elevated serum parathormone after Roux-en-Y gastric bypass. Obes Surg. 2004;14(9):1222–6.CrossRefGoogle Scholar
  14. 14.
    Goode LR, Brolin RE, Chowdhury HA, et al. Bone and gastric bypass surgery: effects of dietary calcium and vitamin D. Obesity Res. 2004;12(1):40–7.CrossRefGoogle Scholar
  15. 15.
    Yajnik CS, Smith RF, Hockaday TD, et al. Fasting plasma magnesium concentrations and glucose disposal in diabetes. Br Med J (Clin Res Ed). 1984;288(6423):1032–4.CrossRefGoogle Scholar
  16. 16.
    Rosolová H, Mayer O Jr, Reaven GM. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations. Metabolism. 2000;49(3):418–20.CrossRefGoogle Scholar
  17. 17.
    Lima Mde L, Pousada J, Barbosa C, et al. Magnesium deficiency and insulin resistance in patients with type 2 diabetes mellitus. Arg Bras Endocrinol Metabol. 2005;49(6):959–63.CrossRefGoogle Scholar
  18. 18.
    Huerta MG, Roemmich JN, Kington ML, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care. 2005;28(5):1175–81.CrossRefGoogle Scholar
  19. 19.
    Djurhuus MS, Henriksen JE, Klitgaard NA, et al. Effect of moderate improvement in metabolic control on magnesium and lipid concentrations in patients with type 1 diabetes. Diabetes Care. 1999;22(4):546–54.CrossRefGoogle Scholar
  20. 20.
    Schnack C, Bauer I, Preqant P, et al. Hypomagnesaemia in type 2 (non-insulin-dependent) diabetes mellitus is not corrected by improvement of long-term metabolic control. Diabetologia. 1992;35(1):77–9.CrossRefGoogle Scholar
  21. 21.
    Paolisso G, Sgambato S, Gambardella A, et al. Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr. 1992;55(6):1161–7.CrossRefGoogle Scholar
  22. 22.
    de Valk H, Verkaaik R, van Rijn H, et al. Oral magnesium supplementation in insulin-requiring type 2 diabetic patients. Diabet Med. 1998;15:1161–7.Google Scholar
  23. 23.
    Eibl N, Kopp H, Nowak H, et al. Hypomagnesemia in type II diabetes: effect of a 3 month replacement therapy. Diabetes Care. 1995;18:188–92.CrossRefGoogle Scholar
  24. 24.
    Widman L, Wester PO, Stegmayer BK, et al. The dose-dependent reduction in blood pressure through administration of magnesium. A double blind placebo controlled cross-over study. Am J Hypertens. 1993;6(1):41–5.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Hans-Erik Johansson
    • 1
    Email author
  • Björn Zethelius
    • 1
  • Margareta Öhrvall
    • 1
  • Magnus Sundbom
    • 2
  • Arvo Haenni
    • 1
  1. 1.Department of Public Health and Caring Sciences/GeriatricsUppsala UniversityUppsalaSweden
  2. 2.Department of Surgical SciencesUppsala University HospitalUppsalaSweden

Personalised recommendations